BeyondSpring Inc. (BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company's pipeline includes plinabulin, a novel anticancer agent being developed for multiple oncology indications. BeyondSpring conducts clinical trials and research aimed at bringing new treatments to patients with unmet medical needs in oncology.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001171843-26-001908 | EDGAR | 136K words |
| 2025-03-27 | 2024-12-31 | 0001171843-25-001758 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001171843-25-007236 | EDGAR | 28K words |
| 2025-08-13 | 2025-06-30 | 0001171843-25-005376 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001171843-25-003088 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001171843-26-001890 | EDGAR | 3K words |
| 2025-12-15 | 0001171843-25-007943 | EDGAR | — |
| 2025-11-21 | 0001171843-25-007497 | EDGAR | — |
| 2025-11-12 | 0001171843-25-007217 | EDGAR | — |
| 2025-09-23 | 0001171843-25-006027 | EDGAR | — |
| 2025-09-16 | 0001171843-25-005922 | EDGAR | — |
| 2025-08-13 | 0001171843-25-005355 | EDGAR | — |
| 2025-07-03 | 0001171843-25-004306 | EDGAR | — |
| 2025-05-12 | 0001171843-25-003087 | EDGAR | — |
| 2025-04-11 | 0001171843-25-002158 | EDGAR | — |
117 total filings indexed. 102 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001677940 |
| Ticker | BYSI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.beyondspringpharma.com |
| Listed | 2017-03-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report